Psicose

Synonyms: DL-Psicose
Psicose (DL-Psicose) 是一种口服有效的糖替代品,可激活 PI3K/Akt/mTOR 通路促进肌肉合成、上调 IGF-1 并下调 Myostatin,通过增加 G6P 活性使线粒体功能障碍恢复正常,增强抗氧化酶活性并减少氧化应激标志物,还能增加衰老小鼠和饮食诱导肥胖小鼠的肌肉量、握力及肌肉重量,改善肥胖和 2 型糖尿病,并可用于年龄相关的肌肉减少症的研究。
产品编号: MS-T19832 纯度: 99.90% CAS No.: 23140-52-5 分子式: C6H12O6 分子量: 180.16
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
询价
50g
询价
询价

产品描述

Psicose (DL-Psicose) 是一种口服有效的糖替代品,可激活 PI3K/Akt/mTOR 通路促进肌肉合成、上调 IGF-1 并下调 Myostatin,通过增加 G6P 活性使线粒体功能障碍恢复正常,增强抗氧化酶活性并减少氧化应激标志物,还能增加衰老小鼠和饮食诱导肥胖小鼠的肌肉量、握力及肌肉重量,改善肥胖和 2 型糖尿病,并可用于年龄相关的肌肉减少症的研究。

生物实验数据

生物活性 Psicose (DL-Psicose) is an orally effective sugar substitute that activates the PI3K/Akt/mTOR pathway to promote muscle synthesis, upregulates IGF-1 and downregulates Myostatin, restores mitochondrial dysfunction to normal by increasing G6P activity, enhances antioxidant enzyme activity and reduces oxidative stress markers, increases muscle mass, grip strength and muscle weight in aged mice and diet-induced obese mice, ameliorates obesity and type 2 diabetes, and can be used for research on age-related sarcopenia.
体内研究
(In Vivo)

Psicose (3% (w/w);通过饮食口服;每日自由摄取;12 周) 可改善老年雄性 C57BL/6J 小鼠的年龄相关性肌少症,表现为肌肉质量与握力提升、肌肉蛋白质合成/降解标志物恢复正常、抗氧化酶活性增强以及代谢指标改善。

Animal Model: C57BL/6J (male, 48 weeks old)
Dosage: 3% (w/w)
Administration: p.o.; ad libitum daily; 12 weeks
Result: Reduced final body weight to 37.59 g, total body weight gain to 1.36 g, and food efficiency ratio to 0.00, all significantly lower than controls.
Reduced liver weight to 3.71 g per 100 g BW, and increased kidney weight to 1.10 g per 100 g BW compared to controls.
Increased left hind leg thickness significantly at weeks 8 and 12 compared to controls.
Increased grip strength (normalized to body weight) significantly compared to controls.
Increased right quadriceps, left quadriceps, and left anterior tibialis weights (normalized to body weight) significantly compared to controls.
Increased muscle fiber cross-sectional area significantly, and reduced muscle collagen (% area) significantly to levels matching young control mice.
Increased insulin-like growth factor 1 (IGF-1) protein expression significantly, and suppressed myostatin protein expression significantly compared to controls.
Increased mRNA expression of myogenic transcription factor genes Myf5, Myf6, and Myogenin significantly compared to controls.
Increased protein levels of Akt, phosphorylated Akt, PI3K, phosphorylated PI3K, AMPK, phosphorylated AMPK, mTOR, and PGC1-α significantly compared to controls.
Upregulated mRNA expression of CISH and CerS1 significantly, and downregulated mRNA expression of Adiponectin, Adipsin, CIDEC, Haptoglobin, Neuronatin, and SCD1 significantly in gastrocnemius tissue compared to controls.
Increased hepatic glucose-6-phosphatase levels and mitochondrial complex IV activity significantly compared to controls.
Reduced hepatic triglyceride levels significantly compared to controls.
Increased hepatic GSH, PON, and GR activities, plus plasma PON activity, significantly compared to controls.
Reduced hepatic H2O2 content significantly compared to controls.
Reduced fasting blood glucose at week 12 significantly compared to controls.
Reduced visceral fat and total adipose tissue weights (normalized to body weight) significantly, and increased the total muscle tissue to total adipose tissue weight ratio significantly compared to controls.
性状 固体
颜色 White to off-white

化学信息

分子量 180.16
分子式 C6H12O6
CAS No. 23140-52-5
别名 DL-Psicose

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (555.06 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM5.5506 mL27.7531 mL55.5062 mL138.7655 mL
5 mM1.1101 mL5.5506 mL11.1012 mL27.7531 mL
10 mM0.5551 mL2.7753 mL5.5506 mL13.8766 mL
15 mM0.3700 mL1.8502 mL3.7004 mL9.2510 mL
20 mM0.2775 mL1.3877 mL2.7753 mL6.9383 mL
25 mM0.2220 mL1.1101 mL2.2202 mL5.5506 mL
30 mM0.1850 mL0.9251 mL1.8502 mL4.6255 mL
40 mM0.1388 mL0.6938 mL1.3877 mL3.4691 mL
50 mM0.1110 mL0.5551 mL1.1101 mL2.7753 mL
60 mM0.0925 mL0.4626 mL0.9251 mL2.3128 mL
80 mM0.0694 mL0.3469 mL0.6938 mL1.7346 mL
100 mM0.0555 mL0.2775 mL0.5551 mL1.3877 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础